Iliyan D. Iliev, PhD, discusses how fluconazole targets gut Candida to improve disease activity in IBD.
News|Articles|March 28, 2024
Beyond Colonoscopy: Shifting Incidence, Mortality Prompts New Era of Colorectal Cancer Screening
Author(s)Abigail Brooks, MA
The recent rise in colorectal cancer incidence and mortality in younger patients has sparked a serious discussion about strategies to increase screening uptake and adherence, raising questions about the role of noninvasive tests versus the traditional “gold standard,” colonoscopy.
Advertisement
Advertisement
Two decades ago, colorectal cancer was the fourth leading cause of cancer-related death in both men and women under 50 years of age – now, it has jumped to the leading cause in men and the second most common cause in women, behind breast cancer.1
Related to this article
Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
Advertisement
Advertisement